PRMT5 catalyses the majority of symmetric dimethylation (SDMA) in mammalian cells, and its association with cancer progression in both solid and haematological disease has prompted the rapid development of small molecule inhibitors that are now in clinical trials [16–20]. The gene discussed is PRMT5; the disease is cancer.